Neurocrine Biosciences NBIX Enterprise value

Enterprise value at other companies

Bristol-Myers SquibbBMY

$152.27B+14.9%

Acadia PharmaceuticalsACAD

$3.56B+36.6%

Crinetics PharmaceuticalsCRNX

$3.74B+21.5%

Solid Biosciences Inc.SLDB

$431.98M+333%

MapLight Therapeutics, Inc. MPLT

$812.61M—

BridgeBio PharmaBBIO

$16.77B+178%

FAQ

What is Neurocrine Biosciences's enterprise value?

Neurocrine Biosciences (NBIX) reported enterprise value of $13.41B in Q1 2026.

How has Neurocrine Biosciences's enterprise value changed year-over-year?

Neurocrine Biosciences's enterprise value increased by 18.5% year-over-year, from $11.32B to $13.41B.

What is the long-term trend for Neurocrine Biosciences's enterprise value?

Over 5 years (2020 to 2025), Neurocrine Biosciences's enterprise value has grown at a 9.1% compound annual growth rate (CAGR), from $9.01B to $13.89B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.